Table 1.
Characteristics of included studies
| Yasuda 2011 | Chaitanya 2017 | Yokota 2017 | |
|---|---|---|---|
| Characteristics of patients | |||
| Number of patients | 24 | 60 | 94 |
| Mean age (years) | 60.4 | 51.5 | 61.0 |
| Dropout | 0 (0.0%) | 4 (6.7%) | 32 (34.0%) |
| Sex (Male/Female) | 14/10 | 59/1 | 77/17 |
| Site of cancer | Oral cavity | Head and neck squamous cell carcinoma | Head and neck cancer, primary tumor |
| TNM staging | |||
|
T1–2 Nany T3–4 Nany |
14 8a |
unclear |
58 36 |
| Type of radiation | Definitive and preoperative | Definitive and post-operative | Definitive or post-operative |
| Combination with chemotherapy | Weekly docetaxel (10 mg/m2) | Weekly CDDP (40 mg/ m2) or Tri-weekly CDDP (100 mg/ m2) | Tri-weekly CDDP (80-100 mg/ m2) |
| Radiation technique |
Conventional 2 Gy/fraction ≥40 Gy irradiation (total) |
3D-CRT or IMRT 2 Gy/fraction in 6–7 weeks Total 60–70 Gy |
3D-CRT or IMRT ≤2.2 Gy/fraction ≥60 Gy |
| Intervention of rebamipide | |||
| Type of mouthwash | Gargle | Gargle | Liquid, rinse and swallow |
| Regimens of rebamipid |
0.1% concentration 6 times daily |
0.1% concentration 6 times daily |
2 and 4% concentration 6 times daily |
| Control | Placebo | Placebo gargle | Placebo liquid |
| Timing of outcomes | At 4 weeks | At the end of chemoradiotherapy | At 57 days |
Cisplatin (CDDP)
aTNM stages were unclear in 2 patients in Yasuda 2011